the spectrum of autoimmune cns disorders · the spectrum of autoimmune cns disorders andrew mckeon,...
TRANSCRIPT
6/20/2017
1
©2017 MFMER | 3643498-1
The Spectrum of Autoimmune CNS Disorders
Andrew McKeon, MD Mayo Clinic
©2017 MFMER | 3643498-2
Disclosures
• I receive research support from Medimmune & Euroimmun
• I have consulted for Medimmune, Euroimmun & Grifols (no personal compensation)
• I have patents applications for GFAP and MAP1B Abs as markers of neurological disease and cancer
6/20/2017
2
©2017 MFMER | 3643498-3
Learning Objectives
• Recognize key characteristics of autoimmune CNS disorders
• Request appropriate antibody testing for those disorders
• Choose appropriate immune therapies
©2017 MFMER | 3643498-4
Outline
• What are Autoimmune CNS Disorders?
• How do patients present?
• Why do they occur?
• How do I evaluate further?
• Basic serum/CSF testing
• Neural antibody (Ab) testing
• Treatment trial in suspected cases ‘The diagnostic test’
6/20/2017
3
©2017 MFMER | 3643498-5
What are Autoimmune CNS Disorders?
©2017 MFMER | 3643498-6
Autoimmune CNS Disorders
• CNS disorders caused by aberrant immune response
• Antigen-specific
• May be paraneoplastic or idiopathic
• Often unified by Ab marker detected in serum or cerebrospinal fluid (CSF)
6/20/2017
4
©2017 MFMER | 3643498-7
How Do Patients Present?
• Subacute onset symptoms
• Fluctuating course
• Can affect any neurological domain
• Often multifocal
• Think rostrocaudal
©2017 MFMER | 3643498-8
Cortex
Visual System
Basal ganglia
Cerebellum
Brainstem
Cervical cord
Thoracic cord
Conus medullaris
Lumbosacral roots
Nerve
roots
Dorsal horn
Anterior horn
Nerve
NMJ
Muscle
6/20/2017
5
©2017 MFMER | 3643498-9
Autonomic Nervous System
Smooth Muscle
Secretory Epithelia
Arteriolar Central
Autonomic Neuron
Autonomic Ganglion
E
N
S
©2017 MFMER | 3643498-10
What Are the Risk Factors?
• Sometimes none
• Coexisting autoimmune disease, e.g. thyroid disease, type 1 diabetes mellitus
• Cancer history
• Smoking history
• Family history of autoimmune disease or cancer
6/20/2017
6
©2017 MFMER | 3643498-11
How Do I Evaluate Further?
• Determine extent of neurological involvement
• Neurological examination
• Mental status testing
• Neuropsychometric testing
• MRI imaging
• Electrophysiology (EEG, EMG, SSEPs)
©2017 MFMER | 3643498-12
How Do I Evaluate Further?
• Ab testing, serum
• Non-neural Abs: e.g. thyroid peroxidase Abs, connective tissue cascade
• Neural Abs: main subject of this course
• CSF testing Protein, white cell count, IgG index and synthesis rate, oligoclonal bands, neural Abs
6/20/2017
7
©2017 MFMER | 3643498-13
Why Do Autoimmune Neurological Diseases Occur?
©2017 MFMER | 3643498-14
McKeon & Pittock, Acta Neuropath 2011
6/20/2017
8
©2017 MFMER | 3643498-15
Neural Abs Overview IgG Antibodies targeting
Neuronal nuclear,
cytoplasmic antigens
Neural cell surface antigens
(ion channels, receptors, synapses)
e.g. ANNA-1, PCA-1, CRMP-5 IgG e.g. VGKC complex Ab,
NMDA-R Ab, GlyR
Oncological therapy Immunotherapy
©2017 MFMER | 3643498-16
Classic Paraneoplastic Autoantibodies Antibody Oncological association
ANNA-1 (anti-Hu) Small-cell carcinoma
ANNA-2 (anti-Ri) Small-cell carcinoma
Breast adenocarcinoma
ANNA-3 Aerodigestive carcinomas
AGNA (SOX-1) Small-cell carcinoma
PCA-1 (anti-Yo) Gynecological adenocarcinomas
Breast adenocarcinoma
PCA-2 Small-cell carcinoma
PCA-Tr (DNER) Hodgkin lymphoma
CRMP-5 IgG (anti-CV2) Small-cell carcinoma
Thymoma
Amphiphysin IgG
Small-cell carcinoma
Breast adenocarcinoma
6/20/2017
9
©2017 MFMER | 3643498-17
Synaptic Autoantibodies Antibody Oncological association
VGKC- complex Small-cell lung carcinoma, thymoma,
adenocarcinoma of breast, prostate
NMDA receptor 50% Ovarian teratoma
AMPA receptor 70% Thymoma, lung carcinoma, breast
carcinoma
GABA-B receptor 50% Small-cell lung carcinoma
P/Q and N type calcium channel Small-cell carcinoma, breast or gynecological
adenocarcinoma
Muscle AChR Thymoma, thymic carcinoma, lung carcinoma,
endometrial carcinoma, prostate carcinoma
Neuronal ganglionic AChR Adenocarcinoma, thymoma, small-cell
carcinoma
NMO-IgG Uncommon (breast adenocarcinoma>
carcinoid, teratoma, thymoma, lymphoma)
©2017 MFMER | 3643498-18
How Are Patients Evaluated in the Laboratory?
6/20/2017
10
©2017 MFMER | 3643498-19
Tissue-based Immunofluorescence
PCA-1 PCA-1 ANNA-1
NMO-IgG NMDA-R IgG
©2017 MFMER | 3643498-20
How are Abs Detected? Indirect Immunofluorescence Screening
• Confirmation by
• Western blot
• Cell based assay
• Immunoprecipitation
• Immunoprecipitation assay screening
• Cell based assay screening
6/20/2017
11
©2017 MFMER | 3643498-21
Examples of Autoimmune CNS Disorders
©2017 MFMER | 3643498-22
Encephalitis
• Memory, mood, personality changes, seizures: Limbic encephalitis
• Diverse autoantibody associations
• ANNA-1, 2 (anti Hu, Ri)
• CRMP-5 IgG
• VGKC complex IgGs
• GAD65 Ab (High titer)
• AMPA, GABA-B receptor Abs
• mGluR5 Ab
6/20/2017
12
©2017 MFMER | 3643498-23
NMDA-R Encephalitis
• Stereotyped course
• Psych → seizures, encephalopathy
• → movement disorder, dysautonomia
• → hypoventilation+coma
• F>M
• 50% have ovarian teratoma
• CSF testing: More sensitive and specific
• Treatment: Steroids/IVIg or PLEX/rituximab/cyclophosphamide
• 80% get to mild or no disability
Titulaer: Lancet Neurology, 2013
©2017 MFMER | 3643498-24
Cognitive Disorders
• Patients may present with cognitive-predominant presentations, not typical for limbic encephalitis
• May have coexisting neurological problems (e.g. tremor, neuropathy)
• Thyroid autoimmunity common
• VGKC complex Abs>GAD65 Ab>N or P/Q type calcium channel Abs> ANNA-1 (anti-Hu)
• Pre- and post objective testing helpful in defining treatment response
Flanagan et al: Mayo Clinic Proceedings, 2010
6/20/2017
13
©2017 MFMER | 3643498-25
Autoimmune Epilepsy
• May have seizure predominant presentation
• Scan may be normal at onset in half
• Dx: EEG, CSF, Ab testing
• VGKC complex Abs > GAD65 Ab > CRMP-5 IgG > Ma2 = NMDA receptor Ab
Quek et al, Arch Neurol 2012
Mesial temporal
Neocortical
temporal
Precentral
Localizations
©2017 MFMER | 3643498-26
GABA-B Receptor IgG
• Limbic encephalitis
• Seizures often prominent
• Some present with status epilepticus
• Rare reports of OMS & ataxia
• Cancer detected in 50% (usually small cell carcinoma)
Lancaster et al, Lancet Neurol 2010; Jeffrey et al, Neurology, 2013 Hoftberger et al, Neurology, 2013
6/20/2017
14
©2017 MFMER | 3643498-27
Opsoclonus-Myoclonus
• Children
• Neuroblastoma
• ANNA-1 in a minority
• Adults
• 15% paraneoplastic
• ANNA-2 > ANNA-1 = NMDA-R Ab
• Frequently idiopathic autoimmune (immunotherapy responsive)
Klaas et al, Arch Neurol 2012
©2017 MFMER | 3643498-28
Opsoclonus OR Myoclonus
• ‘Opsoclonus only’
• ANNA-2 (anti-Ri)
• Breast adenocarcinoma
• ‘Whole body tremor’
• Small amplitude generalized polymyoclonus
• No opsoclonus
• 25% have autoimmune cause
• Occult cancer possible
• VGKC, Alpha 3 ganglionic, CRMP-5 IgG
McKeon et al, Arch Neurol, 2007
6/20/2017
15
©2017 MFMER | 3643498-29
Chorea
• Paraneoplastic or idiopathic autoimmune
• Paraneoplastic
• CRMP-5 IgG
• ANNA-1
• GAD65
• Idiopathic autoimmune
• Lupus, APL Ab syndrome
• CASPR2
O’Toole et al, Neurology 2013
©2017 MFMER | 3643498-30
Chorea
• Paraneoplastic patients more likely
• Older
• Male
• More frequent weight loss
• More frequent coexisting peripheral neuropathy
• Some improved with immunotherapy/cancer therapy
• Idiopathic
• Often milder course
• Improved/resolved with steroids
O’Toole et al, Neurology 2013
6/20/2017
16
©2017 MFMER | 3643498-31
Movement Disorder or Epilepsy?
• 61-year-old male
• Hx of AIDP, IVIg responsive age 43
• Jan 2010: Spells right facial contraction, left facial contraction, then arm posturing
• Diagnosis ‘Psychogenic’ at home
• Video EEG : ictal activity left frontoparietal region
• VGKC complex Ab positive, 2.58 nmol/L
• Neoplastic evaluation negative
• Seizures stopped, EEG normalized with combined immunotherapy/AED
• Mild residual amnesia
Faciobrachial dystonic seizures’, Irani et al, Ann Neurol, 2010
©2017 MFMER | 3643498-32
Cerebellar Ataxia
• Symptoms frequently overlap with brainstem disorders
• Rapid-onset dysarthria, incoordination, gait disturbance, vertigo
• Prototypic disorder
• PCA-1 (anti-Yo) associated cerebellar degeneration in women with mullerian or breast adenocarcinoma
• Other Abs: P/Q-type calcium channel Ab, GAD65 Ab, PCA-Tr, mGluR1 Ab
Peterson et al, Neurology 1992 McKeon et al, Arch Neurol 2010
Cerebellar atrophy
Non-classic disorders also occur
6/20/2017
17
©2017 MFMER | 3643498-33
mGluR1 Ab
Neurological
• Ataxia
• Limbic symptoms (rare, at onset)
• Dysgeusia (40%, at onset)
Cancer
• Lymphoma (HD, non-HD), prostate adenocarcinoma
Sillevis-Smitt, NEJM, 2000 Lopez et al, Neurology, 2016
©2017 MFMER | 3643498-34
Brainstem
• Eye movement disorders
• Dysphagia, dysarthria
• Parkinsonism
• Sleep disorders
• e.g. ANNA-2, MaTa
• Video
• Initial Dx: PSP
• Parkinsonism, narcolepsy-cataplexy
• Ma1, Ma2 Ab positive
• Tonsillar carcinoma
Pittock et al, Ann Neurol 2003; Dalmau et al, Ann Neurol 2004
Adams et al, Arch Neurol 2011
6/20/2017
18
©2017 MFMER | 3643498-35
• First case seen in 1924
• Reported in 1956 with 13 other cases
Moersch, Woltman. Proc Staff Meet Mayo Clin. 1956
©2017 MFMER | 3643498-36
GlyR-IgG in Stiff-Man Syndrome
Mayo, Barcelona JAMA Neurol, 2013
Classic SMS Variant SMS
GAD65-IgG + N=60 GAD65-IgG - N=21
Classic SMS Variant SMS
N=43 N=16 N=4 N=14
PERM
N=2
2 2
PERM
N=1
4 0 1 1
Hyperekplexia
N=1
0
GlyR-IgG + GlyR-IgG +
10/81 patients tested positive (12%, GlyR cell binding assay)
Improved with immunotherapy
5 of 6 GlyR-IgG + patients
7 of 25 GlyR IgG - patients (p=0.02)
6/20/2017
19
©2017 MFMER | 3643498-37
Sleep Disorders
• VGKC complex-IgG
• DPPX-IgG
• IgLON-5-IgG • 8 patients • Chorea, ataxia • Dysarthria, dysphagia • Sleep apnea • Central hypoventilation • IgG4 Ab • Tauopathy
Cornelius et al, Arch Neurol 2010; Tobin et al, Neurology, 2014 Sabater et al, Lancet Neurology, 2014
©2017 MFMER | 3643498-38
DPPX Autoimmunity, Manifestations in 20 Patients
Neurological Cognitive disorders 16
Brainstem/spinal cord disorders 15
Weight loss 12
Myoclonus or tremor 11
Sleep disorder 9
Gastrointestinal dysautonomia 9
Delirium 8
Cerebellar dysfunction 7
Urinary symptoms 7
Psychosis 4
Depression 4
Seizures 2
Cardiac dysrhythmia 3
Diaphoresis 2
Temperature dysregulation 1
Central hyperexcitability PERM (Rigidity + myoclonus 2
Myoclonus 8
Startle 6
Rigidity 6
Brisk reflexes 6
Stiff-man syndrome 0
Cancer B cell neoplasia 2
Tobin et al, Neurology, 2014
6/20/2017
20
©2017 MFMER | 3643498-39
IgLON5
• Sleep disorders
• Brainstem disorders
• Stiff-person spectrum
• Dysautonomia
• ? Treatment responsive
Kidney Cerebellum
SMA Hippocampus
©2017 MFMER | 3643498-40
Paraneoplastic Myelopathy
• Subacute or insidious onset
• Lung, breast, kidney, thyroid, ovary/endometrium, melanoma, or other
• Amphiphysin IgG, CRMP-5 IgG, ANNA-1, PCA-1, ANNA-3
• Minority improve with treatment
• 50% Wheelchair bound
Flanagan et al, Neurology, 2011.
6/20/2017
21
©2017 MFMER | 3643498-41
Neuromyelitis Optica
• Autoimmune CNS disorder distinct from MS
• Severe (including bilateral) optic neuritis
• Myelitis: Long spinal cord lesions
• Intractable hiccoughs, nausea, vomiting
• Encephalopathy (mimicking ADEM) in children
• Can improve dramatically with steroids, PLEX, IVIg
• Need immunosuppression to maintain remission
Wingerchuk, Lancet Neurology 2007 Jacob et al, JNNP 2012
©2017 MFMER | 3643498-42
NMO-IgG/AQP4-IgG
• Distinguishes NMO from classical MS
• Specificity >90%
• Tissue IF: 58% sensitivity
• New antigen-specific assays 70-80% sensitivity
Lennon, et al Lancet 2004 Fryer, et al, N2, 2014
6/20/2017
22
©2017 MFMER | 3643498-43
MOG Ab
• Assay: Cell-based format
• IgG1 anti-human secondary Ab
• Syndromes
• Optic neuritis
• Myelitis
• ADEM or ADEM-like
• Brainstem disorders
• NMO
• Clinical course
• Monophasic, relapsing often ++ steroid responsive
Kitley et al, Neurology, 2012 Rostasy et al, Arch Neurol 2012
©2017 MFMER | 3643498-44
• Inflammatory CNS disorder
• Meningitis
• Encephalitis
• Myelitis
• Inflammatory CSF
• Sometimes paraneoplastic
• Steroid responsive
6/20/2017
23
©2017 MFMER | 3643498-45
GM
WM
CC
A
B
C
D
E
F
G H I
J
©2017 MFMER | 3643498-46
GFAP-IgG
Flanagan et al, Ann Neurol, 2017
6/20/2017
24
©2017 MFMER | 3643498-47
GFAP-IgG
Flanagan et al, Ann Neurol, 2017
©2017 MFMER | 3643498-48
GFAP-IgG
Flanagan et al, Ann Neurol, 2017
6/20/2017
25
©2017 MFMER | 3643498-49
Evaluation for Cancer
• Based on: Specific Ab finding(s)
OR
• Age, sex, family history
• CT chest, abdomen, pelvis
• Pelvic ultrasound (incl. transvaginal views)
• Testicular ultrasound
• Mammogram
• Exploratory surgery
©2017 MFMER | 3643498-50
PET-CT
McKeon et al, Arch Neurol, 2010
*Increased cancer detection rate ~ 20%
6/20/2017
26
©2017 MFMER | 3643498-51
Treatment: Principles
• Trials of immunotherapy
• Measure improvement objectively
• Determining if short-term or long term treatment required
• Consider steroid-sparing agent
©2017 MFMER | 3643498-52
Cytotoxic T Cell Mediated Disorders
• Paraneoplastic disorders
• Do not generally have good responses to steroids, IVIg or plasma exchange
• General approach
• Oncological therapy (surgery, chemotherapy, radiation therapy)
• Cyclophosphamide
Vernino et al, Neuro Oncol. 2004;6:55-62
6/20/2017
27
©2017 MFMER | 3643498-53
Antibody-Mediated Disorders (Definite or Possible)
• Acute (early important)
• Corticosteroids
• Intravenous immune globulin (IVIg)
• Plasma exchange
• Chronic
• Mycophenolate mofetil
• Azathioprine
• Rituximab, cyclophosphamide
©2017 MFMER | 3643498-54
McKeon, Lennon, Pittock, Continuum, 2010.
Confirms diagnosis Chronic treatment
Continue acute IV therapy, and taper or
Oral prednisone taper and
Oral azathioprine or Oral mycophenolate mofetil
or Other options
Objective baseline measurements
Acute treatment, “Diagnostic Test”
IV methylprednisolone or
IVIg or
Plasma exchange
Consider
alternative
acute therapy
or no further
therapy
No
improvement
6/20/2017
28
©2017 MFMER | 3643498-55
Summary
• Autoimmune CNS disorders are important to consider
• Potentially treatable
• May be indicative of occult cancer
• Clues may emanate from
• History
• Examination
• Serum & CSF Ab evaluations
• Response to treatment
©2017 MFMER | 3643498-56
Thank You!
Andrew McKeon
507-266-3196
6/20/2017
29
©2017 MFMER | 3643498-57
Questions & Discussion